ClinicalTrials.gg
RecruitingNCT05600842Updated Nov 20, 2026

De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

An interventional study of Intensity-Modulated Radiation Therapy (IMRT) in HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by University of California, Irvine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of California, Irvine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.
Updated Nov 20, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
366th of 994
62 · median 41
Started
2022
with 56 others
No phase
72 of 1,099
17 open now
Primary completion
2028-11
later than 262 of 346 live
Registered
863rd of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 366th largest by planned enrollment of the 994 interventional ones that give a count, is one of 57 that started in 2022, is one of 72 with no phase, reaches primary completion later than 262 of the 346 other live ones, and was the 863rd registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This is a single-arm, interventional study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.

03

Conditions studied

  • HPV Positive Oropharyngeal Squamous Cell Carcinoma
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologically (histologically or cytologically) proven (from primary lesion and/or lymph nodes) diagnosis of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma. HPV-positivity will be defined as tumors that are p16-positive by immunohistochemistry. Numerous studies have demonstrated near 100% agreement between p16 and HPV for patients with oropharyngeal cancer. As such, the use of p16 has been accepted as an appropriate surrogate for HPV status; and testing for p16 has been routinely performed for OPSCC since 2009.
  • Patients with TNM staging of T1-2N1M0 or T3N0-N1M0 (AJCC 8th edition) and ≤10 pack year smoking history are eligible;
  • History/physical examination within 6 weeks prior to registration, including assessment of weight and recent weight loss;
  • Age ≥ 18;
  • PET/CT within 6 weeks prior to registration;
  • Patients must sign a study-specific form prior to study entry.
  • Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial.

Exclusion criteria

Exclusion Criteria:

  • Prior invasive (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years;
  • Patients who have had initial surgical treatment other than the diagnostic of the primary site or nodal sampling of the neck disease are excluded;
  • Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable;
  • Receipt of prior radiotherapy that would result in overlap with proposed field.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    De-escalated radiotherapy

    Radiation: Intensity-Modulated Radiation Therapy (IMRT)

Interventions

  • RadiationIntensity-Modulated Radiation Therapy (IMRT)

    IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.

06

What researchers measure

Primary outcomes

  1. 2-Year Progression-Free Survival

    Progression-free survival (PFS) is defined as the time from registration to disease progression or death from any cause.

    Time frame: Given the natural history of this disease, PFS will be monitored up to 2 years from registration

Secondary outcomes

  1. Overall survival

    Survival time will be measured from the date of randomization to the date of death due to any cause or last follow-up.

    Time frame: Given the natural history of this disease, overall survival will be monitored for up to 2 years from registration

  2. Local-regional control

    Local-regional control is defined as the absence of local and/or regional progression.

    Time frame: Given the natural history of this disease, local-regional control will be monitored up to 2 years from registration

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2028, 72 months after the start.

Of 116 non-industry interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 72 months is above that.

Counting every sponsor, half of 127 studies reached it within 59 months; a quarter within 34 and three quarters within 90.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Nov 2026 → Nov 2028 and completion Nov 2026 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Nov 1, 2022
StartActual
Nov 3, 2022
Primary completionEst.
Nov 2028was Nov 2026
CompletionEst.
Nov 2028was Nov 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2026→Nov 2028
Nov 20, 2026
Study completion
Nov 2026→Nov 2028
Nov 20, 2026
Enrollment
111→62
Nov 20, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPathologically (histologically or cytologically) proven (from primary lesion and/or lymph nodes) diagnosis of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma. HPV-positivity will be defined as tumors that are p16-positive by immunohistochemistry. Numerous studies have demonstrated near 100% agreement between p16 and HPV for patients with oropharyngeal cancer. As such, the use of p16 has been accepted as an appropriate surrogate for HPV status; and testing for p16 has been routinely performed for OPSCC since 2009.
  • ChangedBefore Clinical stage I, II, or III disease (AJCC Eighth Edition); Note: Patients with M1 tumors (distant metastases) are not eligible;Now Patients with TNM staging of T1-2N1M0 or T3N0-N1M0 (AJCC 8th edition) and ≤10 pack year smoking history are eligible;
Nov 20, 2026
Design
Study type Observational→Interventional
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Nov 2026→Nov 2028
    Study completion Nov 2026→Nov 2028
    Enrollment 111→62
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPathologically (histologically or cytologically) proven (from primary lesion and/or lymph nodes) diagnosis of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma. HPV-positivity will be defined as tumors that are p16-positive by immunohistochemistry. Numerous studies have demonstrated near 100% agreement between p16 and HPV for patients with oropharyngeal cancer. As such, the use of p16 has been accepted as an appropriate surrogate for HPV status; and testing for p16 has been routinely performed for OPSCC since 2009.
    • ChangedBefore Clinical stage I, II, or III disease (AJCC Eighth Edition); Note: Patients with M1 tumors (distant metastases) are not eligible;Now Patients with TNM staging of T1-2N1M0 or T3N0-N1M0 (AJCC 8th edition) and ≤10 pack year smoking history are eligible;
    Design Study type Observational→Interventional
    + 2 other changes: description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05600842
Responsible party
Eric Chen (Assistant Professor, University of California, Irvine) — Principal investigator
First posted
Nov 1, 2022
Start date
Nov 3, 2022
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Chao Family Comprehensive Cancer Center University of California, Irvine
Contact
ucstudy@uci.edu
877-827-8839
University of California Irvine Medical
Contact
Eric Chen, MD
principal investigator · Chao Family Comprehensive Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion